Vismodegib
Hedgehog Pathway Inhibitors
Sold as Erivedge
- Drug class
- Hedgehog Pathway Inhibitors
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 8
Overview
Vismodegib is an active pharmaceutical ingredient in the Hedgehog Pathway Inhibitors group (L01XJ). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 6 | February 20, 2026 |
| EU European Union | EMA | 1 | January 22, 2026 |
| CA Canada | Health Canada | 1 | March 22, 2025 |
GBUnited Kingdom· MHRA
6 products
Uses
1).
How to take
Erivedge should only be prescribed by or under the supervision of a specialist physician experienced in the management of the approved indication. Posology The recommended dose is one 150 mg capsule taken once daily. Missed doses If a dose is missed, patients should be instructed not to take the missed dose but to resume with the next scheduled dose.
Duration of treatment In clinical studies, treatment with Erivedge was continued until disease progression or until unacceptable toxicity. Treatment interruptions of up to 4 weeks were allowed based on individual tolerability. Benefit of continued treatment should be regularly assessed, with the optimal duration of therapy varying for each individual patient.
2). Of a total number of 138 patients in 4 clinical studies of Erivedge in advanced basal cell carcinoma, approximately 40 % of patients were ≥ 65 years old and no overall differences in safety and efficacy were observed between these patients and younger patients.
Renal impairment Mild and moderate renal impairment is not expected to impact the elimination of vismodegib and no dose adjustment is needed. Very limited data is available in patients with severe renal impairment. Patients with severe renal impairment should be carefully monitored for adverse reactions.
5 x ULN < TB < 3 x ULN, AST any • severe: 3 x ULN < TB < 10 x ULN, AST any Paediatric population The safety and efficacy of Erivedge in children and adolescents aged below 18 years have not been established. 3), this medicinal product should not be used in children and adolescents aged below 18 years.
2). The capsules must not be opened, to avoid unintended exposure to patients and health care providers.
This is not medical advice. Consult a qualified healthcare professional.
Side effects & warnings
3%). Tabulated list of adverse reactions ADRs are presented in table 1 below by system organ class (SOC) and absolute frequency.
Frequencies are defined as:
Very common ( ≥ 1/10) Common ( ≥ 1/100 to < 1/10) Uncommon ( ≥ 1/1,000 to < 1/100) Rare ( ≥ 1/10,000 to < 1/1,000) Very rare ( < 1/10,000) Not known (cannot be estimated from the available data). Within each frequency grouping, ADRs are presented in the order of decreasing seriousness.
The safety of Erivedge has been evaluated in clinical studies with 138 patients treated for advanced basal cell carcinoma (aBCC), which includes both metastatic BCC (mBCC) and locally advanced BCC (laBCC). In four open label phase 1 and 2 clinical studies patients were treated with at least one dose of Erivedge monotherapy at doses ≥ 150 mg.
Doses > 150 mg did not result in higher plasma concentrations in clinical studies and patients on doses > 150 mg have been included in the analysis. Additionally, safety was assessed in a post approval study that included 1215 aBCC patients evaluable for safety and treated with 150 mg.
In general the safety profile observed was consistent in both mBCC and laBCC patients and across studies as described below. 0 except where noted. *Of the 138 patients with advanced BCC, 10 were WCBP. Amongst these women, amenorrhoea was observed in 3 patients (30 %).
MedDRA = Medical Dictionary for Regulatory Activities. **Includes preferred terms: liver function test abnormal, blood bilirubin increased, gamma-glutamyl transferase increased, aspartate aminotransferase increased, alkaline phosphatase increased, liver hepatic enzyme increased.
*** Observed in patients during a post-approval study with 1215 safety evaluable patients. 4) ***** Cases of drug induced liver injury have been reported in patients during post-marketing use. ******Cases of SCAR (including SJS/TEN, DRESS and AGEP) have been reported in patients during post- marketing use.
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions (see details below).
uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store
6). 3). 3). Criteria for a woman of childbearing potential (WCBP) A WCBP is defined in the Erivedge Pregnancy Prevention Programme as: • a sexually mature female who • has menstruated at any time during the previous 12 consecutive months, • has not undergone a hysterectomy or a bilateral oophorectomy, or who does not have medically-confirmed permanent premature ovarian failure, • does not have a XY genotype, Turner’s syndrome, or uterine agenesis, • becomes amenorrhoeic following cancer therapy, including treatment with Erivedge.
Counselling For a WCBP Erivedge is contraindicated in a WCBP who does not comply with the Erivedge Pregnancy Prevention Programme. 6) while she is taking Erivedge, unless she commits to not having sexual intercourse (abstinence), • She must tell her healthcare provider if any of the following occur during treatment and for 24 months after her final dose: • If she becomes pregnant or think for any reason that she may be pregnant, • If she misses her expected menstrual period, • If she stops using contraception unless she commits to not having sexual intercourse (abstinence), • If she needs to change contraception during treatment, • She must not breast-feed while taking Erivedge and for 24 months after the final dose.
For men Vismodegib is present in semen. 6), • He will tell his healthcare provider if his female partner becomes pregnant while he is taking Erivedge or during the 2 months after his final dose. For health care providers (HCP) HCPs must educate the patients so they understand and acknowledge all the conditions of the Erivedge Pregnancy Prevention Programme.
6). 6). Pregnancy testing In a WCBP, a medically supervised pregnancy test, conducted by a heath care provider, should be performed within 7 days prior to initiating treatment and monthly during treatment. Pregnancy tests should have a minimum sensitivity of 25 mIU/mL as per local availability.
Patients who present with amenorrhoea during treatment with Erivedge should continue monthly pregnancy testing while on treatment. Prescribing and dispensing restrictions for WCBP The initial prescription and dispensing of Erivedge should occur within a maximum of 7 days of a negative pregnancy test (day of pregnancy test = day 1).
Prescriptions of Erivedge should be limited to 28 days of treatment and continuation of treatment requires a new prescription. Educational material In order to assist health care providers and patients to avoid embryonic and foetal exposure to Erivedge the Marketing Authorisation Holder will provide educational materials (Erivedge Pregnancy Prevention Programme) to reinforce the potential risks associated with the use of Erivedge.
Effects on post-natal development Premature fusion of the epiphyses and precocious puberty have been reported in paediatric patients exposed to Erivedge. Due to the long drug elimination half-life, these events may occur or progress after drug discontinuation.
In animal species, vismodegib has been shown to cause severe irreversible changes in growing teeth (degeneration/necrosis of odontoblasts, formation of fluid-filled cysts in the dental pulp, ossification of the root canal, and haemorrhage) and closure of the epiphyseal growth plate.
3). Blood donation Patients should not donate blood while taking Erivedge and for 24 months after the final dose. Semen donation Male patients should not donate semen while taking Erivedge and for 2 months after the final dose. g. 5). Severe cutaneous adverse reactions Severe cutaneous adverse reactions (SCARs) including cases of Stevens-Johnson syndrome/Toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms […]
This is not medical advice. Consult a qualified healthcare professional.
Who should not take it
1. 6). 6). 5).
This is not medical advice. Consult a qualified healthcare professional.
EUEuropean Union· EMA
1 product
Uses
1).
How to take
Erivedge should only be prescribed by or under the supervision of a specialist physician experienced in the management of the approved indication. Posology The recommended dose is one 150 mg capsule taken once daily. Missed doses If a dose is missed, patients should be instructed not to take the missed dose but to resume with the next scheduled dose.
Duration of treatment In clinical studies, treatment with Erivedge was continued until disease progression or until unacceptable toxicity. Treatment interruptions of up to 4 weeks were allowed based on individual tolerability. Benefit of continued treatment should be regularly assessed, with the optimal duration of therapy varying for each individual patient.
2). Of a total number of 138 patients in 4 clinical studies of Erivedge in advanced basal cell carcinoma, approximately 40 % of 3 patients were ≥ 65 years old and no overall differences in safety and efficacy were observed between these patients and younger patients.
Renal impairment Mild and moderate renal impairment is not expected to impact the elimination of vismodegib and no dose adjustment is needed. Very limited data is available in patients with severe renal impairment. Patients with severe renal impairment should be carefully monitored for adverse reactions.
5 x ULN < TB < 3 x ULN, AST any severe: 3 x ULN < TB < 10 x ULN, AST any Paediatric population The safety and efficacy of Erivedge in children and adolescents aged below 18 years have not been established. 3), this medicinal product should not be used in children and adolescents aged below 18 years.
Method of administration Erivedge is for oral use. 2). The capsules must not be opened, to avoid unintended exposure to patients and health care providers.
This is not medical advice. Consult a qualified healthcare professional.
Side effects & warnings
3%). Tabulated list of adverse reactions ADRs are presented in table 1 below by system organ class (SOC) and absolute frequency.
Frequencies are defined as:
Very common ( ≥ 1/10) Common ( ≥ 1/100 to < 1/10) Uncommon ( ≥ 1/1,000 to < 1/100) Rare ( 1/10,000 to < 1/1,000) Very rare ( < 1/10,000) Not known (cannot be estimated from the available data). Within each frequency grouping, ADRs are presented in the order of decreasing seriousness.
The safety of Erivedge has been evaluated in clinical studies with 138 patients treated for advanced basal cell carcinoma (aBCC), which includes both metastatic BCC (mBCC) and locally advanced BCC (laBCC). In four open label phase 1 and 2 clinical studies patients were treated with at least one dose of Erivedge monotherapy at doses 150 mg.
Doses > 150 mg did not result in higher plasma concentrations in clinical studies and patients on doses > 150 mg have been included in the analysis. Additionally, safety was assessed in a post approval study that included 1215 aBCC patients evaluable for safety and treated with 150 mg.
In general the safety profile observed was consistent in both mBCC and laBCC patients and across studies as described below. 0 except where noted. *Of the 138 patients with advanced BCC, 10 were WCBP. Amongst these women, amenorrhoea was observed in 3 patients (30 %).
MedDRA Medical Dictionary for Regulatory Activities. **Includes preferred terms: liver function test abnormal, blood bilirubin increased, gamma-glutamyl transferase increased, aspartate aminotransferase increased, alkaline phosphatase increased, liver hepatic enzyme increased.
*** Observed in patients during a post-approval study with 1215 safety evaluable patients. 4) ***** Cases of drug induced liver injury have been reported in patients during post-marketing use. ******Cases of SCAR (including SJS/TEN, DRESS and AGEP) have been reported in patients during post- marketing use.
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare 10 professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
6). 3). 3). Criteria for a woman of childbearing potential (WCBP) A WCBP is defined in the Erivedge Pregnancy Prevention Programme as: a sexually mature female who has menstruated at any time during the previous 12 consecutive months, has not undergone a hysterectomy or a bilateral oophorectomy, or who does not have medically-confirmed permanent premature ovarian failure, does not have a XY genotype, Turner’s syndrome, or uterine agenesis, 4 becomes amenorrhoeic following cancer therapy, including treatment with Erivedge.
Counselling For a WCBP Erivedge is contraindicated in a WCBP who does not comply with the Erivedge Pregnancy Prevention Programme. 6) while she is taking Erivedge, unless she commits to not having sexual intercourse (abstinence), She must tell her healthcare provider if any of the following occur during treatment and for 24 months after her final dose: If she becomes pregnant or think for any reason that she may be pregnant, If she misses her expected menstrual period, If she stops using contraception unless she commits to not having sexual intercourse (abstinence), If she needs to change contraception during treatment, She must not breast-feed while taking Erivedge and for 24 months after the final dose.
For men Vismodegib is present in semen. 6), He will tell his healthcare provider if his female partner becomes pregnant while he is taking Erivedge or during the 2 months after his final dose. For health care providers (HCP) HCPs must educate the patients so they understand and acknowledge all the conditions of the Erivedge Pregnancy Prevention Programme.
6). 6). 5 Pregnancy testing In a WCBP, a medically supervised pregnancy test, conducted by a heath care provider, should be performed within 7 days prior to initiating treatment and monthly during treatment. Pregnancy tests should have a minimum sensitivity of 25 mIU/mL as per local availability.
Patients who present with amenorrhoea during treatment with Erivedge should continue monthly pregnancy testing while on treatment. Prescribing and dispensing restrictions for WCBP The initial prescription and dispensing of Erivedge should occur within a maximum of 7 days of a negative pregnancy test (day of pregnancy test = day 1).
Prescriptions of Erivedge should be limited to 28 days of treatment and continuation of treatment requires a new prescription. Educational material In order to assist health care providers and patients to avoid embryonic and foetal exposure to Erivedge the Marketing Authorisation Holder will provide educational materials (Erivedge Pregnancy Prevention Programme) to reinforce the potential risks associated with the use of Erivedge.
Effects on post-natal development Premature fusion of the epiphyses and precocious puberty have been reported in paediatric patients exposed to Erivedge. Due to the long drug elimination half-life, these events may occur or progress after drug discontinuation.
In animal species, vismodegib has been shown to cause severe irreversible changes in growing teeth (degeneration/necrosis of odontoblasts, formation of fluid-filled cysts in the dental pulp, ossification of the root canal, and haemorrhage) and closure of the epiphyseal growth plate.
3). Blood donation Patients should not donate blood while taking Erivedge and for 24 months after the final dose. Semen donation Male patients should not donate semen while taking Erivedge and for 2 months after the final dose. g. 5). Severe cutaneous adverse reactions Severe cutaneous adverse reactions (SCARs) including cases of Stevens-Johnson syndrome/Toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms […]
This is not medical advice. Consult a qualified healthcare professional.
Who should not take it
1. 6). 6). 5).
This is not medical advice. Consult a qualified healthcare professional.
Brands in European Union (1)
CACanada· Health Canada
1 product
Uses
AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS .................................................................................
5 ADVERSE REACTIONS ................................................................................................. 13 DRUG INTERACTIONS .................................................................................................
18 DOSAGE AND ADMINISTRATION ............................................................................. 19 OVERDOSAGE ...............................................................................................................
21 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 21 STORAGE AND STABILITY ......................................................................................... 23 SPECIAL HANDLING INSTRUCTIONS ......................................................................
23 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 23 PART II: SCIENTIFIC INFORMATION .............................................................................. 25 PHARMACEUTICAL INFORMATION .........................................................................
25 CLINICAL TRIALS ......................................................................................................... 25 DETAILED PHARMACOLOGY ....................................................................................
29 TOXICOLOGY ................................................................................................................ 31 REFERENCES .................................................................................................................
33 PART III: CONSUMER INFORMATION............................................................................. 34 ERIVEDGE® Product Monograph Page 3 of 37 PrERIVEDGE® vismodegib PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION Route of Administration Pharmaceutical Form/Strength Clinically Relevant Non-medicinal Ingredients Oral Capsule, 150 mg Capsule content: Lactose monohydrate.
For a complete listing see Dosage Forms, Composition and Packaging section. INDICATIONS AND CLINICAL USE ERIVEDGE (vismodegib) is indicated for the treatment of adult patients with histologically confirmed metastatic basal cell carcinoma (BCC) or locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy.
The indication is granted market authorization based on objective response rate (ORR) demonstrated in a single-arm Phase II trial (see CLINICAL TRIALS). Overall survival (OS) benefit in a single-arm trial cannot be confirmed. In the pivotal trial, the majority of the clinical responses occurred within 16 weeks.
Benefit of continued treatment should be regularly assessed, with the optimal duration of therapy varying for each individual patient (see CLINICAL TRIALS). Distribution Restrictions ERIVEDGE is only available through a controlled distribution program called the ERIVEDGE Pregnancy Prevention Program (EPPP).
Under this program, only prescribers and pharmacies registered with the program are able to prescribe and dispense the product, respectively. In addition, ERIVEDGE can only be dispensed to patients who are registered and meet all the conditions of the EPPP.
ca.
Geriatrics (≥ 65 years of age):
Of the total number of patients in clinical studies of ERIVEDGE with advanced basal cell carcinoma, approximately 40% of patients were ≥ 65 years old. Although no overall differences in safety and efficacy were observed between these patients and younger patients, an insufficient number of elderly were enrolled in the clinical studies to rule out the risk of reduced ERIVEDGE® Product Monograph Page 4 of 37 effectiveness or increased toxicity in this patient population (see WARNINGS AND PRECAUTIONS, Special Populations and CLINICAL STUDIES).
Elderly patients should be treated with caution and monitored for adverse events. No specific dose adjustments are recommended for the elderly (see DOSAGE AND ADMINISTRATION).
Pediatrics (< 18 years of age):
The safety and efficacy of ERIVEDGE in pediatric patients has not been established (see WARNINGS AND PRECAUTIONS, Special Populations). Irreversible premature fusion of the epiphyses has been reported in pediatric patients exposed to ERIVEDGE (see WARNINGS AND PRECAUTIONS, Effects on Post-Natal Development).
Premature fusion can progress after discontinuation of treatment. Due to safety concerns, ERIVEDGE is contraindicated in children and adolescents aged below 18 years (see CONTRAINDICATIONS and TOXICOLOGY). CONTRAINDICATIONS ERIVEDGE (vismodegib) is contraindicated in: Female patients who are pregnant and females at risk of becoming pregnant (see WARNINGS AND PRECAUTIONS, Special Populations).
Breastfeeding female patients (see WARNINGS AND PRECAUTIONS, Special Populations). Female patients of childbearing potential (FCBP) who do not comply with the ERIVEDGE Pregnancy Prevention Program (see WARNINGS AND PRECAUTIONS, Special Populations).
Male patients who do not comply with the contraceptive measures of the ERIVEDGE Pregnancy Prevention Program (see WARNINGS AND PRECAUTIONS, Special Populations). Children and adolescents aged below 18 years (see TOXICOLOGY and WARNINGS AND PRECAUTIONS, Effects on Post-Natal Development).
Patients who are hypersensitive to vismodegib or to any ingredient in the formulation (see DOSAGE FORMS, COMPOSTION AND PACKAGING for a complete listing). ERIVEDGE® Product Monograph Page 5 of 37 WARNINGS AND PRECAUTIONS Serious Warnings and Precautions ERIVEDGE (vismodegib) should be initiated and monitored only under the supervision of a […]
Side effects & warnings
Serious Warnings and Precautions ERIVEDGE (vismodegib) should be initiated and monitored only under the supervision of a physician qualified in the use of cancer therapies and with a full understanding of the risks of ERIVEDGE therapy and monitoring requirements.
ERIVEDGE can cause embryo-fetal death or severe birth defects (see WARNINGS AND PRECAUTIONS, Special Populations). ERIVEDGE has not been studied in patients with severe renal impairment (see WARNINGS AND PRECAUTIONS). ERIVEDGE is not recommended for use in patients with severe hepatic impairment since limited data are available in these patients (see WARNINGS AND PRECAUTIONS).
ERIVEDGE is available only through a controlled distribution program called the ERIVEDGE Pregnancy Prevention Program (EPPP). ERIVEDGE can cause irreversible premature fusion of the epiphyses in pediatric patients (see CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, Effects on Post- Natal Development and Pediatrics and ADVERSE REACTIONS, Post-Market Adverse Events and TOXICOLOGY).
ERIVEDGE can cause severe cutaneous adverse reactions including Toxic Epidermal Necrolysis (TEN) and Stevens Johnson Syndrome (SJS). Patients experiencing a severe cutaneous adverse reaction should discontinue treatment with ERIVEDGE and seek prompt medical evaluation (see WARNINGS AND PRECAUTIONS, Skin and ADVERSE REACTIONS, Post-Market Adverse Events).
General Embryo-fetal death or severe birth defects ERIVEDGE may cause embryo-fetal death or severe birth defects when administered to a female who is pregnant (see CONTRAINDICATIONS). Hedgehog pathway inhibitors, such as vismodegib, have been demonstrated to be embryotoxic, fetotoxic and/or teratogenic in multiple animal species at exposures lower than the human exposures at the recommended dose of 150 mg/day (see TOXICOLOGY, Teratogenicity).
ERIVEDGE can cause severe malformations, including craniofacial anomalies, midline defects and limb defects (see TOXICOLOGY). ERIVEDGE must not be used during pregnancy. Effects on Post-Natal Development Irreversible premature fusion of the epiphyses (EPF) and precocious puberty have been reported in pediatric patients exposed to ERIVEDGE.
In some cases of EPF, fusion progressed after drug discontinuation (see INDICATIONS AND CLINICAL USE and WARNINGS AND PRECAUTIONS, Special Populations). ERIVEDGE® Product Monograph Page 6 of 37 In animal species, ERIVEDGE has been shown to cause severe irreversible changes in the male reproductive systems (not reversible after a 4-week recovery period), growing teeth (degeneration/necrosis of odontoblasts, formation of fluid-filled cysts in the dental pulp, ossification of the root canal, and hemorrhage) and closure of the epiphyseal growth plate.
These findings occurred at clinically relevant doses and indicate a potential risk for short stature, tooth deformities and future reproductive problems in infants and children (see WARNINGS AND PRECAUTIONS, Sexual Function/Reproduction and TOXICOLOGY).
Blood Donation Patients must not donate blood or blood products while on treatment (including dose interruptions) and for 24 months after treatment discontinuation. The safety of ERIVEDGE is based on single-arm clinical trials of patients with advanced BCC (aBCC).
Due to the nature of the design of the trials, it is not always possible to assign, nor to exclude, causality to a particular adverse event. As such, the following sections below describe reported adverse events based on clinical trial experience, irrespective of relatedness to ERIVEDGE (except where noted).
Carcinogenesis and Mutagenesis ERIVEDGE tested negative in a battery of in vitro and in vivo genotoxicity assays, and formal carcinogenicity studies of vismodegib have not been completed. However, pilomatricoma (a benign subcutaneous neoplasm) was observed at clinically relevant exposures in rats administered vismodegib.
Pilomatricoma has not been reported in clinical trials with vismodegib, and the relevance of this finding to patients is therefore uncertain (see DETAILED PHARMACOLOGY and TOXICOLOGY). Patients with advanced BCC have an increased risk of developing cutaneous squamous cell carcinoma (cuSCC).
Cases of cuSCC have been reported in advanced BCC patients (aBCC) treated with ERIVEDGE. Therefore, all patients should be monitored routinely while taking ERIVEDGE. Cardiovascular Cardiac-related adverse events such as atrial fibrillation, cardiac flutter, cardiac failure, restrictive cardiomyopathy, angina, myocardial infarction, and left ventricular dysfunction have been observed in aBCC patients treated with ERIVEDGE.
Fatal cases of acute myocardial infarction and ischemic stroke were reported. Typically, Grade ≥ 3 cardiac adverse events occurred in patients with a significant prior history of cardiac disease. In addition, vascular- related disorders observed include Grade ≥ 3 hypertension and orthostatic hypotension (see ADVERSE REACTIONS, Clinical Trial Adverse Drug Reactions).
Thromboembolic events such as thrombosis, deep vein thrombosis, and pulmonary embolism (including a fatal case) have been reported (see ADVERSE REACTIONS, Clinical Trial Adverse Drug Reactions). ERIVEDGE® Product Monograph Page 7 of 37 Endocrine and Metabolism Decreased appetite and dehydration are considered related to treatment with ERIVEDGE.
4%) patients at 12-months post-treatment discontinuation. Electrolyte abnormalities have been observed in aBCC patients treated with ERIVEDGE including Grade 3/Grade 4 hyponatremia, and Grade 3 hypokalemia (see ADVERSE REACTIONS, Clinical Trial Adverse Drug Reactions).
Gastrointestinal Nausea, vomiting, diarrhea, constipation, and abdominal pain are all considered related to treatment with ERIVEDGE. In addition, cases of Grade 3/Grade 4 and a fatal case of gastrointestinal hemorrhage, small intestinal obstruction, and aphagia were observed in patients treated with ERIVEDGE (see ADVERSE REACTIONS, Clinical Trial Adverse Drug […]
This is not medical advice. Consult a qualified healthcare professional.
Brands in Canada (1)
Drug interactions
Known interactions involving Vismodegib. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB000310850 · revised February 20, 2026
- [2]European Medicines Agency · EMEA/H/C/002602 · revised January 22, 2026
- [3]Health Canada (DPD) · 02409267 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.